MedTrace Logo

Journavx to Treat Pain After Thumb Basal Joint Arthroplasty

NCT07723352 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-07-23

No results posted yet for this study

Summary

The purpose of this study is to find out how well suzetrigine, a newly FDA-approved non-opioid pain medication, works to relieve pain after thumb basal joint replacement surgery. The researchers believe that suzetrigine may provide effective pain relief during recovery without the use of opioid medications.

Conditions

  • Thumb Basal Joint Osteoarthritis
  • Postoperative Pain
  • Joint Replacement Surgery
  • Joint Replacement

Interventions

DRUG

suzetrigine 100mg

Participants will receive the recommended dosing for suzetrigine, which consists of a 100 mg oral loading dose taken in the recovery room prior to discharge, followed by 50 mg doses taken orally every 12 hours for 5 days, totaling 11 doses.

DRUG

Acetaminophen

As part of the multimodal pain regimen, participants will also receive acetaminophen (Tylenol) (500 mg, every 4 hours, or 1000 mg, every 8 hours)

Sponsors & Collaborators

  • Rothman Institute Orthopaedics

    lead OTHER

Principal Investigators

  • Camilo Restrepo, MD · Rothman Orthopaedic Institute

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-21
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07723352 on ClinicalTrials.gov